Sabiston Ch52 — Colorectal Neoplasia & Colon Cancer Surgery
Citation: Galandiuk S, Netz U, Morpurgo E, Tosato SM, Abu-Freha N, Ellis CT. Chapter 52: Colon and Rectum. In: Sabiston Textbook of Surgery, 21st ed. Elsevier; pp. 1364–1379 (this chunk, up to the start of “Rectal Cancer”).
Source type: Textbook chapter — reference source, not a primary study. See Sabiston Ch52 - Diverticular Disease, Obstruction & Pseudo-Obstruction for the general note on how this chapter is used in the wiki.
This is chunk 4 of the chapter (chunk 1: diverticular disease/obstruction/Ogilvie syndrome; chunk 2: IBD; chunk 3: infectious/ischemic colitis). Chunk 5 will pick up exactly where this leaves off: rectal cancer preoperative evaluation, staging, and surgery (TME, LAR, APR).
Scope of this chunk
Pages 1364–1379: colorectal cancer molecular genetics and consensus molecular subtypes; polyps (nonneoplastic, serrated, neoplastic, malignant) and postpolypectomy surveillance; all five hereditary CRC syndromes (FAP, MAP, PJS, JPS, Lynch); TNM staging and additional prognostic factors; and colon cancer surgical technique (general principles plus right-sided, transverse, splenic flexure, and left-sided resections) and obstructing colon cancers.
Filing
Given the volume, this chunk produced eight new pages:
- Colorectal Cancer Molecular Pathways — chromosomal instability, CIMP, MSI mutator pathway, EMT, CMS1–4.
- Colorectal Polyps — nonneoplastic/serrated/neoplastic polyps, malignant polyp management, postpolypectomy surveillance.
- Hereditary Colorectal Cancer Syndromes — overview/comparison, linking to:
- Familial Adenomatous Polyposis (FAP) (includes MUTYH-associated polyposis)
- Lynch Syndrome
- Hamartomatous Polyposis Syndromes (Peutz-Jeghers, juvenile polyposis)
- Colorectal Cancer Staging (TNM) — TNM/AJCC framework, prognostic factors.
- Colon Cancer Resection — general principles and technique by tumor location.
- Obstructing Colon Cancer — presentation, diagnosis, management by side.
Relevance
The molecular pathways and hereditary syndrome content is a solid, fairly stable skeleton (these frameworks don’t shift quickly) but has no primary trial data behind any individual claim — good candidates for future primary-literature ingests are any of the specific surveillance-interval studies (Table 52.6), the Lynch syndrome extended-vs-limited-resection question (explicitly flagged in the text as lacking a prospective RCT), or stenting-as-bridge-to-surgery trial data for obstructing left-sided cancers. The TNM staging content should be treated as a summary, not a replacement for the current AJCC manual, if a specific staging decision is on the line.